115.06
전일 마감가:
$116.69
열려 있는:
$115.01
하루 거래량:
707.04K
Relative Volume:
0.90
시가총액:
$6.68B
수익:
$507.44M
순이익/손실:
$-187.69M
주가수익비율:
-35.18
EPS:
-3.271
순현금흐름:
$-39.06M
1주 성능:
+6.87%
1개월 성능:
+6.80%
6개월 성능:
+36.83%
1년 성능:
+33.68%
Glaukos Corporation Stock (GKOS) Company Profile
명칭
Glaukos Corporation
전화
949-367-9600
주소
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
GKOS
Glaukos Corporation
|
115.06 | 6.68B | 507.44M | -187.69M | -39.06M | -3.271 |
|
ABT
Abbott Laboratories
|
101.83 | 176.95B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
332.07 | 127.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.42 | 110.95B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
61.86 | 91.93B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
80.84 | 46.61B | 6.07B | 1.06B | 1.34B | 1.8063 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Buy |
| 2025-05-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 개시 | Truist | Buy |
| 2023-11-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-14 | 재개 | Stephens | Overweight |
| 2022-10-04 | 개시 | Needham | Buy |
| 2022-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2022-02-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2021-11-03 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 업그레이드 | Citigroup | Sell → Neutral |
| 2020-12-09 | 개시 | Oppenheimer | Perform |
| 2020-11-17 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 개시 | Jefferies | Hold |
| 2020-03-05 | 개시 | Citigroup | Sell |
| 2020-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-01-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2019-12-12 | 다운그레이드 | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 개시 | BTIG Research | Neutral |
| 2018-08-30 | 개시 | Berenberg | Hold |
| 2018-08-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 재확인 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-04-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-01 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-03-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-01-06 | 업그레이드 | Stifel | Hold → Buy |
| 2016-10-27 | 개시 | Wells Fargo | Outperform |
모두보기
Glaukos Corporation 주식(GKOS)의 최신 뉴스
Citi Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $135 - Moomoo
A Look At Glaukos (GKOS) Valuation As Epioxa Showcased At ASCRS Annual Meeting - simplywall.st
Glaukos Stock 5-Day Winning Spree: Stock Climbs 13% - trefis.com
Does Glaukos (GKOS) Using Epioxa at ASCRS Hint at a Broader Corneal-Health Strategy Shift? - finance.yahoo.com
Glaukos to Present Multiple Scientific Abstracts at ASCRS Annual Meeting - National Today
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refrac - PharmiWeb.com
Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS - MarketBeat
Q4 2024 Glaukos Corp Earnings Call Transcript - GuruFocus
Glaukos (NYSE: GKOS) CDO reports RSU tax withholding transactions - Stock Titan
Glaukos (NYSE: GKOS) CFO withholds 1,589 shares for RSU tax obligations - stocktitan.net
Glaukos (GKOS) president uses 3,169 shares to cover tax withholding - stocktitan.net
Glaukos (GKOS) CEO gifts 180,308 shares to family trust - Stock Titan
Glaukos Corp. Experiences Evaluation Revision Amidst Mixed Market Signals and Volatility - Markets Mojo
Cash per share of Glaukos Corp – DUS:6GJ - TradingView
Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules - ChartMill
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC - MarketBeat
GLAUKOS (GKOS) CDO has 5,798 shares withheld to cover RSU tax - stocktitan.net
Glaukos Corporation (GKOS) Stock forecasts - Yahoo Finance UK
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance
GKOS PE Ratio & Valuation, Is GKOS Overvalued - intellectia.ai
SG Americas Securities LLC Purchases 49,492 Shares of Glaukos Corporation $GKOS - MarketBeat
Why Glaukos Stock Jumped Over 20% After-Hours Today - MSN
Alex Thurman: ‘Phenomenal Year’ for Glaukos - Orange County Business Journal
Price-Driven Insight from (GKOS) for Rule-Based Strategy - Stock Traders Daily
GKOS SEC FilingsGlaukos Corp 10-K, 10-Q, 8-K Forms - stocktitan.net
Aug Chart Watch: Does Glaukos Corporation stock have upside surprise potential2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Glaukos breaks ground on $80M R&D, manufacturing facility in Alabama - MSN
Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock - MarketBeat
Glaukos SVP Thurman sells $267k in GKOS stock - Investing.com
Glaukos SVP Thurman sells $267k in GKOS stock By Investing.com - Investing.com South Africa
Glaukos (NYSE: GKOS) president reports new stock and option grants - Stock Titan
Glaukos (NYSE: GKOS) CFO gets new equity awards and sells shares - Stock Titan
Glaukos Corporation (NYSE:GKOS): Is Breakeven Near? - 富途牛牛
Glaukos launches Epioxa, boosts growth in corneal treatments - MSN
Riverbridge Partners LLC Sells 34,475 Shares of Glaukos Corporation $GKOS - MarketBeat
Assenagon Asset Management S.A. Has $20.59 Million Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos (GKOS) Is Up 5.5% After Launching Incision-Free Epioxa Therapy For KeratoconusWhat's Changed - simplywall.st
Vanguard realigns reporting; Vanguard subsidiaries to report GKOS holdings (GKOS) - Stock Titan
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 1,521 Shares of Stock - MarketBeat
Glaukos CFO Thurman sells $160k in shares By Investing.com - Investing.com South Africa
Glaukos CFO Thurman sells $160k in shares - Investing.com
Glaukos (GKOS) CEO uses 2,744 shares to cover equity tax withholding - Stock Titan
Glaukos (GKOS) president sees 15,118 shares withheld to cover tax obligations - Stock Titan
Glaukos (NYSE: GKOS) insider plans sale of 2,511 vested shares - stocktitan.net
Glaukos (GKOS) affiliate files to sell 1,521 shares after vesting - Stock Titan
Glaukos Corp Stock Faces Monthly Pressure Amid Analyst Optimism and Glaucoma Innovation Push - AD HOC NEWS
Piper Sandler reiterates Glaukos stock rating on growth outlook - Investing.com UK
Piper Sandler reiterates Glaukos stock rating on growth outlook By Investing.com - Investing.com Australia
Why is Glaukos (GKOS) down 14.7% since last earnings report? - MSN
JPMorgan Chase & Co. Has $54.65 Million Stock Position in Glaukos Corporation $GKOS - marketbeat.com
Glaukos Introduces Epioxa, Accelerating Expansion in Corneal Therapy - Bitget
Glaukos Corporation (GKOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):